Minutes of the 19th Annual General Meeting of the Shareholders of MOLECULAR PARTNERS AG, held at 9:00 a.m. on 17 April 2024 at JED Events, Zürcherstrasse 39,.
First subject dosed with Nykode Therapeutics' T cell focused SARS-CoV-2 vaccine candidate. This is part of the ongoing phase 1/2 two-arm clinical trial VB-D-01 designed to specifically address emerging
Investegate announcements from Nykode Therapeutics, Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate
Multi-target agreement covers five programs focused on off-the-shelf vaccines for cancer and infectious disease Nykode Therapeutics (formerly Vaccibody) to receive an upfront payment of USD